http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104146999-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2014-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104146999-B |
| titleOfInvention | Rubescensine A and Docetaxel attenuation synergistic antineoplastic pharmaceutical compositions and application thereof |
| abstract | The present invention provides a kind of attenuation synergistic antineoplastic pharmaceutical compositions and application thereof, and wherein, the activeconstituents playing attenuation synergistic is rubescensine A and Docetaxel. Kinds of tumor cells is had obvious cooperative synergism effect by pharmaceutical composition of the present invention, and obviously reduces for multiple human normal cell toxicity alone compared with medicine, decreases pharmaceutical composition to the injury of body, plays obvious synergism and attenuation. Due to the attenuation synergistic effect that pharmaceutical composition of the present invention is special, it is possible to be widely used in the treatment of human cancer. |
| priorityDate | 2014-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.